Novel therapeutic agents for the treatment of hepatitis C virus infection by inhibiting NPC1L1
Hepatitis C is a blood‐borne infectious disease that is caused by the Hepatitis C virus (HCV), affecting the liver. The infection is often asymptomatic, but once established, chronic infection can cause inflammation of the liver (chronic hepatitis). This condition can progress to scarring of the liver (fibrosis), and advanced scarring (cirrhosis). In some cases, those with cirrhosis will go on to develop liver failure or other complications of cirrhosis, including liver cancer. An estimated 150‐200 million people worldwide are infected with hepatitis C. A major obstacle in the treatment of HCV‐related disease has been the lack of effective, well tolerated therapeutics.